Direct answer: Patient recruitment in clinical trials is the process of identifying potentially relevant people, approaching them through approved channels, providing appropriate study information, checking initial fit and supporting them toward formal screening and informed consent. Recruitment is broader than advertising and does not itself establish eligibility: the qualified study team conducts formal screening and makes the clinical decision.
What the recruitment process actually includes
A useful recruitment model starts before the first phone call and ends later than a lead form. It connects study feasibility, approved outreach, responsive contact, pre-screening, formal site screening, informed consent and enrolment. Treating those steps as one operational system makes handoffs visible without collapsing their legal and clinical differences.
Define the population, site capacity, approved materials and measurable funnel.
Use approved sources and messages to invite potentially relevant people.
Contact interested people promptly and explain the next step clearly.
Capture answers to approved preliminary questions for site review.
The qualified study team verifies eligibility through the protocol-defined process.
Complete informed consent and the study’s required enrolment steps.
Not every study uses the same channels or division of work. The approved protocol, ethics opinion, applicable law, contracts and delegation records remain authoritative.
Recruitment, pre-screening, screening and enrolment are not synonyms
| Stage | Purpose | Typical output | Decision boundary |
|---|---|---|---|
| Recruitment | Create an ethical route from awareness to a site conversation | Interested, contactable candidates | No eligibility decision |
| Pre-screening | Identify obvious potential matches or mismatches using approved questions | Structured responses for review | Preliminary only |
| Screening | Apply protocol procedures and verify inclusion and exclusion criteria | Documented eligibility assessment | Qualified study team |
| Enrolment | Bring an eligible, consenting participant into the trial | Enrolled participant | Requires the study’s formal process |
ClinicalTrials.gov defines eligibility criteria as the inclusion requirements and exclusion characteristics that govern who may participate. ICH Good Clinical Practice places trial-related medical decisions with an appropriately qualified investigator or sub-investigator. Automation can organise recruitment work, but it should not blur that accountability.
Who is responsible for patient recruitment?
There is no single universal operating model. A sponsor may design the recruitment strategy and retain oversight, a CRO may perform responsibilities transferred in writing, and sites carry out local activities through trained and delegated teams. Investigators remain responsible for trial conduct at their site and for the clinical decisions assigned to them.
- Sponsors: align the recruitment plan with trial design, feasibility, oversight and approved materials.
- CROs: execute the responsibilities transferred to them and maintain quality controls for that work.
- Sites: confirm local capacity, use current approved documents, protect participant experience and manage clinical handoffs.
- Investigators: oversee site conduct and ensure qualified people make medical decisions.
The responsibility map should be written before activation. “The vendor handles recruitment” is not a responsibility map.
A practical operating framework: reach, response, review
Reach the population the protocol is meant to study
Start with realistic site data and patient pathways, not channel assumptions. Ask where potential participants receive care, which barriers make participation difficult, and whether the approved information is understandable and accessible.
Make response an owned workflow
Define who receives each lead, which consent or permission exists for contact, what the first contact may say, how attempts are recorded and when a person is handed to the site. A lead list without ownership is only inventory.
Protect the clinical review
Pre-screening outputs should make source, question, answer and uncertainty easy for the study team to review. A concise “possible match” label must never be presented as a clinical eligibility determination.
What this means for sponsors, CROs and sites
Sponsors
Design one measurable recruitment system across channels and sites. Specify approvals, oversight and escalation paths before comparing vendors.
CROs
Make every handoff testable: lead received, contact attempted, response structured, site review completed and next action assigned.
Sites
Validate workload and local patient pathways. Reserve qualified staff time for the decisions and conversations that cannot be delegated to automation.
Where Nacar fits — and where it does not
Nacar supports the operational path from candidate contact to structured pre-screening responses and follow-up, using questions approved for the study. The site team reviews the responses and decides who moves forward. Nacar does not diagnose, obtain the study’s formal clinical eligibility evidence or make the final eligibility decision.
Frequently asked questions
What does recruiting mean in a clinical trial?
It means finding potentially relevant people, informing them through approved materials and supporting them into the site’s screening and consent pathway. It is an operational and ethical process, not simply lead generation.
Who makes the final eligibility decision?
The appropriately qualified study team does, using the protocol and required clinical information. A pre-screen, campaign or software output can support review but should not be treated as the eligibility decision.
Is pre-screening part of recruitment?
Usually, yes. Pre-screening is a preliminary recruitment step used to identify potential fit and organise site review. Formal screening is distinct and follows the protocol-defined process.
Can patient recruitment be automated?
Administrative and communication steps can be automated within an approved workflow. Human oversight, informed consent and clinical eligibility responsibilities remain with the authorised people and organisations.
Primary sources
By
Pedro Torrecillas
Founder & CEO, Nacar.ai
Pedro has spent more than a decade building recruitment companies and products. At Nacar, he applies that operating experience to clinical-trial patient recruitment.
Published: · Updated:
